Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chKTi-SPP-DM1
- Development stage
- Discontinued
- Lead developer
- ImmunoGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
chKTi-SPP-DM1 is a non-targeting antibody-drug conjugate (ADC) developed by ImmunoGen for use as a negative control in preclinical research. It consists of a chimeric human IgG1 monoclonal antibody directed against soybean trypsin inhibitor (KTi), an antigen not found in human or mouse tissues, conjugated to the cytotoxic maytansinoid DM1 via the cleavable disulfide linker N-succinimidyl-3-(2-pyridyldithio)propionate (SPP). In experimental models, such as those for small cell lung cancer (SCLC), chKTi-SPP-DM1 serves to establish the baseline for antigen-independent toxicity and to confirm that the efficacy of targeted ADCs (like lorvotuzumab mertansine) is due to specific binding to the intended tumor antigen rather than non-specific payload delivery.
- Other names
- chimeric anti-soybean trypsin inhibitor antibody-DM1 conjugate
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on chKTi-SPP-DM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chKTi-SPP-DM1.